Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials

降钙素基因相关肽 偏头痛 荟萃分析 医学 降钙素 单克隆抗体 随机对照试验 内科学 单克隆 药理学 抗体 免疫学 神经肽 受体
作者
Jennifer Robblee,Sameh M. Hakim,John Reynolds,Teshamae Monteith,Niushen Zhang,Meredith Barad
出处
期刊:Headache [Wiley]
卷期号:64 (5): 547-572 被引量:2
标识
DOI:10.1111/head.14693
摘要

Abstract Objective To compare calcitonin gene–related peptide monoclonal antibodies (CGRP mAbs) versus nonspecific oral migraine preventives (NOEPs). Background Insurers mandate step therapy with NOEPs before approving CGRP mAbs. Methods Databases were searched for class I or II randomized controlled trials (RCTs) comparing CGRP mAbs or NOEPs versus placebo for migraine prevention in adults. The primary outcome measure was monthly migraine days (MMD) or moderate to severe headache days. Results Twelve RCTs for CGRP mAbs, 5 RCTs for topiramate, and 3 RCTs for divalproex were included in the meta‐analysis. There was high certainty that CGRP mAbs are more effective than placebo, with weighted mean difference (WMD; 95% confidence interval) of −1.64 (−1.99 to −1.28) MMD, which is compatible with small effect size (Cohen's d −0.25 [−0.34 to −0.16]). Certainty of evidence that topiramate or divalproex is more effective than placebo was very low and low, respectively (WMD −1.45 [−1.52 to −1.38] and −1.65 [−2.30 to −1.00], respectively; Cohen's d −1.25 [−2.47 to −0.03] and −0.48 [−0.67 to −0.29], respectively). Trial sequential analysis showed that information size was adequate and that CGRP mAbs had clear benefit versus placebo. Network meta‐analysis showed no statistically significant difference between CGRP mAbs and topiramate (WMD −0.19 [−0.56 to 0.17]) or divalproex (0.01 [−0.73 to 0.75]). No significant difference was seen between topiramate or divalproex (0.21 [−0.45 to 0.86]). Conclusions There is high certainty that CGRP mAbs are more effective than placebo, but the effect size is small. When feasible, CGRP mAbs may be prescribed as first‐line preventives; topiramate or divalproex could be as effective but are less well tolerated. The findings of this study support the recently published 2024 position of the American Headache Society on the use of CGRP mAbs as the first‐line treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
KevenDing完成签到,获得积分10
3秒前
wulalala发布了新的文献求助30
4秒前
CipherSage应助loski采纳,获得10
4秒前
我是老大应助loski采纳,获得10
4秒前
完美世界应助loski采纳,获得10
5秒前
李健应助loski采纳,获得10
5秒前
欣喜沛芹发布了新的文献求助10
7秒前
可爱的函函应助橙色小人采纳,获得10
8秒前
ED应助多发论文采纳,获得10
10秒前
10秒前
量子星尘发布了新的文献求助10
10秒前
Owen应助机智思真采纳,获得10
11秒前
传奇3应助loski采纳,获得10
12秒前
万能图书馆应助自觉的凛采纳,获得10
14秒前
18秒前
积极幻桃应助ssjjzhou采纳,获得10
19秒前
讨厌科研完成签到,获得积分10
20秒前
23秒前
Xw发布了新的文献求助10
25秒前
26秒前
失眠的霸完成签到,获得积分10
27秒前
ChatGPT发布了新的文献求助10
28秒前
30秒前
多发论文完成签到,获得积分20
31秒前
31秒前
32秒前
su发布了新的文献求助10
32秒前
Xw关闭了Xw文献求助
32秒前
大个应助fjm采纳,获得10
35秒前
而为发布了新的文献求助30
35秒前
机智思真发布了新的文献求助10
35秒前
木樨316完成签到,获得积分10
35秒前
38秒前
花花完成签到 ,获得积分10
40秒前
沉默的小天鹅应助耀阳采纳,获得10
40秒前
lilila666完成签到,获得积分10
40秒前
42秒前
43秒前
43秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989378
求助须知:如何正确求助?哪些是违规求助? 3531442
关于积分的说明 11254002
捐赠科研通 3270126
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173